June 11, 2020 / 12:47 PM / 2 months ago

BRIEF-Diffusion - Entire Phase 1A/1B Trial Will Enroll About 224 Patients And Is Expected To Last Approximately 12 Months

Diffusion Pharmaceuticals Inc:

* DIFFUSION PHARMACEUTICALS FILES CLINICAL TRIAL APPLICATION FOR EUROPEAN PHASE 1A/1B STUDY OF TSC IN COVID-19 PATIENTS

* DIFFUSION - SUBMISSION OF CTA TO ROMANIAN NATIONAL AGENCY FOR MEDICINES & MEDICAL DEVICES FOR EUROPEAN PHASE 1A/1B STUDY OF TSC IN COVID-19 PATIENTS

* DIFFUSION - ENTIRE PHASE 1A/1B TRIAL WILL ENROLL ABOUT 224 PATIENTS AND IS EXPECTED TO LAST APPROXIMATELY 12 MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below